

## 別紙 4

## 研究成果の刊行に関する一覧表

## 書籍

著者氏名	論文タイトル名	書籍全体の編集者名	書籍名	出版社名	出版地	出版年	ページ
大川 翔, 清水栄司	不安または恐怖関連症群 総説	神庭重信, 三村将, 松 下正明	不安または恐怖関連症群 強迫症 ストレス関連症群 パーソナリティ症 講座 精神疾患の臨床	中山書店	東京	2021	
荒井穂菜 美, 清水栄 司	全般不安症	神庭重信, 三村将, 松 下正明	不安または恐怖関連症群 強迫症 ストレス関連症群 パーソナリティ症 講座 精神疾患の臨床	中山書店	東京	2021	

## 雑誌

発表者氏名	論文タイトル名	発表誌名	巻号	ページ	出版年
Aoki Y, Takaesu Y, Suzuki M, Okajima I, Takeshima M, Shimura A, Utsumi T, Kotori N, Yamashita H, Kuriyama K, Watanabe N, Mishima K.	Development and acceptability of a decision aid for chronic insomnia considering discontinuation of benzodiazepine hypnotics.	Neuropsychopharmacol Rep	42 (2)	10-20	2021

<p>Nakagome Kazuyuki, Yokoi Yuma, Nakagawa Atsuo, Tani Masayuki, Nishioka Gen-taro, Yoshimura Naoki, Furukawa Toshiaki, <u>Watanabe Koichiro</u>, Mimura Masaru, Iwanami Akira, Abe Takayuki.</p>	<p>Acceptability of escitalopram versus duloxetine in outpatients with depression who did not respond to initial second-generation antidepressants: a randomized, parallel-group, non-inferiority trial.</p>	<p>J Affective Disorders</p>	<p>282</p>	<p>1011-1020</p>	<p>2021</p>
<p>Sakurai Hitoshi, Yasui-Furukori Norio, Suzuki Takefumi, Uchida Hiroyuki, <u>Watanabe Hajime</u>, <u>Watanabe Koichiro</u>, <u>Inada Ken</u>, Sugawara Kikuchi Yuka, Kikuchi Tomashiaki, Katsuki Asuka, Kishida Ikuko, Kato Masaki.</p>	<p>Medical Education Panel of the Japanese Society of Clinical Neuropsychopharmacology. Pharmacological Treatment of Schizophrenia: Japanese Expert Consensus.</p>	<p>Pharmacopsychiatry.</p>	<p>54 (2)</p>	<p>60-67</p>	<p>2021</p>
<p>Adachi Naoto, Aizekawa Takaharu, Edagawa Kouji, Goto Eiichiro, Hongo Seiji, Kato Masaki, Kitatsumoto Eiichi, Kikuchi Toshiaki, Kubota Yukihiisa, Miki Kazuhira, Nakagawa Atsuo, <u>Tsuboi Takashi</u>, Ueda Hitoshi, <u>Watanabe Koichiro</u>, <u>Watanabe Yoichiro</u>, Yasui-Furukori Norio, Yoshimura Reij.</p>	<p>Estimated model of psychotropic polypharmacy for bipolar disorder: Analysis using patients' and practitioners' parameters in the MUSUBI study.</p>	<p>Hum Psychopharmacol.</p>	<p>36 (2)</p>		<p>2021</p>

Hayasaka Tomonari, <u>Takaesu Yoshikazu</u> , Nagashima Izumi, Futada Miku, Nozaki Kazuhiro, Katagiri Takeshi, Imamura Yayoi, Kurihara Mariko, Oe Yuki, <u>Tsuboi Takashi</u> , <u>Watanabe Koichiro</u> .	Factors Associated With Time to Achieve Employment Through Occupational Support Programs in Patients With Mood Disorders: 1 Year Naturalistic Study.	Front Psychiatry.	12		2021
Katagiri Takeshi, <u>Takaesu Yoshikazu</u> , Kurihara Mariko, Oe Yuki, Ishii Miho, Onoda Naoko, Hayasaka Tomonari, Kanda Yuta, Imamura Yayoi, <u>Watanabe Koichiro</u> .	Improving Employment Through Interpersonal Psychotherapy: A Case Series of Patients With Treatment-Refractory Depression.	Front Psychiatry.	12		2021
Kanda Yuta, <u>Takaesu Yoshikazu</u> , Kobayashi Minami, Komada Yoko, Futenma Kunihiro, Okajima Isana, <u>Watanabe Koichiro</u> , Inoue Yuchichi.	Reliability and validity of the Japanese version of the Biological Rhythms Interview of assessment in neuropsychiatry-self report for delayed sleep-wake phase disorder.	Sleep Med.	81	288-293	2021

Numata Shusuke, Nakataki Masahito, Hasegawa Naomichi, Takaesu Yoshikazu, Takeshima Masahiro, Onitsuka Toshiki, Nakamura Tomoshinori, Edagawa Reon, Edo Hiroaki, Miura Kenichi, Matsumoto Junya, Yasui-Furukori Norio, Kishimoto Takashi, Tsuboi Takashi, Yasuda Yuka, Furihata Ryoju, Muraoka Hiroaki, Ochi Shinichiro, Nagasawa Tatsuya, Koyou Yoshitaka, Murata Atsunobu, Katsumoto Eiichi, Ohi Kazutaka, Hishimoto Akitoyo, Inada Ken, Watanabe Koichi, Hashimoto Ryota.	Improvements in the degree of understanding the treatment guidelines for schizophrenia and major depressive disorder in a nationwide dissemination and implementation study.	Neuropsychopharmacol Rev	41 (2)	199-206	2021
Ayani Nobutaka, Morimoto Takeshi, Sakura Mio, Kikuchi Toshiki, Watanabe Koichi, Narumoto Jin.	Antipsychotic Polypharmacy Is Associated With Adverse Drug Events in Psychiatric inpatients. The Japanese Adverse Drug Events Study.	J Clin Psychopharmacol.	41 (4)	397-402	2021
Aoki Yumi, Tsuboi Takashi, Takaesu Yoshikazu, Watanabe Koichi, Nakayama Kazuhiro, Kinoshita Yasuhito, Kayama Mami.	Development and field testing of a decision aid to facilitate shared decision making for adults newly diagnosed with attention-deficit hyperactivity disorder.	Health Expect			2021

<p>Ogasawara Kazuyoshi, Numata Shusuke, Hasegawa Naomi, Nakataki Masahito, Makinodan Manabu, Ohi Kazutaka, Takeshima Masahiro, <u>Tsuboi Takashi</u>, Hashimoto Naoki, Onitsuka Toshiaki, Muraoka Hiroyuki, Hori Hikaru, Ichihashi Kayo, Inagaki Takahiko, Yasui-Furukori Norio, Hishimoto Akitoyo, Sugiyama Nobuhiro, Fukumoto Kentaro, Nagasawa Tatsuya, Matsumoto Junya, <u>Takaesu Yoshikazu</u>, Furihata Ryuji, Nemoto Kiyotaka, Nakamura Toshinori, Usami Masahide, Miura Kenichiro, Fujimoto Michiko, Tagata Hiromi, Yamada Hisashi, Komatsu Hiroshi, Ochi Shinichiro, Atake Kiyokazu, Katsumoto Eiichi, Kido</p>	<p>Subjective assessment of participants in education programs on clinical practice guidelines in the field of psychiatry.</p>	<p>Neuropsychopharmacol Res</p>	<p>Mar 10</p>		<p>2022</p>
---	--	---------------------------------	---------------	--	-------------

Mikio, Kishimoto Taishiro, Suwa Taro, Yamamura Satoshi, Iga Jun-Ichi, Iida Hitoshi, Inada Ken, Watanabe Koichiro, Hashimoto Ryota.					
--	--	--	--	--	--

<p>Yamada Hisashi, Motoyama Mikuni, Hasegawa Naomi, Miura Kenichiro, Matsumoto Junya, Ohi Kazutaka, Yasui-Furukori Norio, Numata Shunsuke, Takeshima Masahiro, Sugiyama Nobuhiro, Nagasawa Tatsuya, Kubota Chika, Atake Kiyokazu, <u>Tsuboi</u> <u>Takashi</u>, Ichihashi Kayo, Hashimoto Naoki, Inagaki Takahiro, <u>Takaesu</u> <u>Yoshikazu</u>, Iga Jun-Ichi, Hori Hikaru, Onitsuka Toshiaki, Komatsu Hiroshi, Hishimoto Akitooy, Fukumoto Kentaro, Fujimoto Michiko, Nakamura Toshinori, Nemoto Kiyotaka, Furihata Ryuj, Yamamura Satoshi, Yamagata Hrotaka, Ogasawara Kazuyoshi, Katsumoto Eiichi, Murata Atsunobu, Iida Hitoshi, Ochi</p>	<p>A dissemination and education programme to improve the clinical behaviours of psychiatrists in accordance with treatment guidelines for schizophrenia and major depressive disorders: the Effectiveness of Guidelines for Dissemination and Education in Psychiatric Treatment (EGUIDE) project.</p>	<p>BJPsych Open. n.</p>	<p>Apr 21;8 (3)</p>		<p>2022</p>
--	---	-----------------------------	-------------------------	--	-------------



Shinichiro, Makinodan Manabu, Kido Mikio, Kishimoto Taishiro, Yasuda Yuka, Usami Masahide, Suwa Taro, <u>Inada Ken</u> , <u>Watanabe</u> <u>Koichiro</u> , Hashimoto Ryota.					
<u>Aoki Y</u> , <u>Takaesu</u> Y, Baba H, Igai JI, Hori H, Inoue T, <u>Mishima</u> <u>K</u> , Tajika A, Kan to M.	Development and acceptability of a decision aid for major depressive disorder considering discontinuation of antidepressant treatment after remission.	Neuropsychopharmacol Rep.	42(3)	306-314	2022
Tsujii N, Okada T, Usami M, Kuma wabara H, Fujita J, Negoro H, Iida J, <u>Aoki Y</u> , <u>Takaesu</u> Y, Saito T.	Decision aid development and its acceptability among adults with attention-deficit/hyperactivity disorders regarding treatment discontinuation after remission.	PCN Rep.	1		2022
<u>Aoki Y</u> , Yaju Y, Utsumi T, Sanyal L, Stormshak M, <u>Takaesu Y</u> , <u>Watanabe</u> K, Watanabe N, Duncan E, Edwards AG.	Shared decision-making interventions for people with mental health conditions.	Cochrane Database Syst Rev.	11(11)		2022
Takeshima M, <u>Aoki</u> <u>Y</u> , Ie K, Katsumoto E, Tsuruta E, <u>Tsuboi</u> <u>T</u> , Inada K, Kise M, <u>Watanabe</u> K, <u>Mishima</u> K, <u>Takaesu</u> Y.	Attitudes and Difficulties Associated with Benzodiazepine Discontinuation.	Int J Environ Res Public Health.	19(23)	159-190	2022

<p>Takeshima M, Enomoto M, Ogasawara M, Kudo M, Itoh Y, Yoshizawa K, Fujiwara D, <u>Takaesu Y</u>, <u>Mishima K</u>.</p>	<p>Changes in psychotropic polypharmacy and high-potency prescription following policy change: Findings from a large scale Japanese claims database.</p>	<p>Psychiatry Clin Neurosci.</p>	<p>76(9)</p>	<p>475-477</p>	<p>2022</p>
<p><u>Takaesu Y</u>, Suzuki M, Moline M, Pinner K, Inabe K, Nishi Y, Kuriyama K.</p>	<p>Effect of discontinuation of lemborexant following long-term treatment of insomnia disorder: Secondary analysis of a randomized clinical trial.</p>	<p>Clin Transl Sci.</p>	<p>Dec;23</p>		<p>2022</p>
<p>Furihata Ryuji, Otsuki Rei, Hasegawa Naomi, <u>Tsuboi Takashi</u>, Numata Shusuke, Yasui-Furukori Norio, Kashiwayagi Hiroko, Horihikaru, Ochi Shinichiro, Muraoka Hiroyuki, Onitsuka Toshiaki, Komatsu Hiroshi, Takeshima Masahiro, Hishimoto Akitoyo, Nagasawa Tatsuya, <u>Takaesu Yoshikazu</u>, Nakamura Toshinori, Asami Takeshi, Miura Kenichiro, Matsumoto Junya, Ohi Kazutaka, Yasuda Yuka, Iida Hitoshi, Ogasawara Kazuyoshi, Hashimoto Naoki, Ichihashi Kayo, Yamada Hisashi, <u>Watanabe Koichiro</u>, <u>Inada Ken</u>, Hashimoto Ryota.</p>	<p>Hypnotic medication use among inpatients with schizophrenia and major depressive disorder: results of a nationwide study.</p>	<p>Sleep Med.</p>	<p>Jan;89</p>	<p>23-30</p>	<p>2022</p>

<u>Yoshikazu</u> <u>Takaesu,</u> Hitoshi Sakurai, <u>Yumi</u> <u>Aoki, Masahiro</u> Takehima, Kenya Ie, Kentarō Matsui, Tomohiro Utsumi, Akiyoshi Shimura, <u>Isa</u> Okajima, Nozomu Kotorii, Hidehisa Yamashita, Masahiro Suzuki, Kenichi Kuriyama, Eiji Shimizu, <u>Kazuo</u> <u>Mishima,</u> <u>Koichiro</u> Watanabe, <u>Ken</u> <u>Inada.</u>	Treatment Strategy for Insomnia Disorder: Japanese Expert Consensus.	Front Psychiatry.	In press.		2023
Aoki Y, Takeshi ma M, Tsuboi T, Katsumoto E, Uchi dagawa K, Inada K, Watanabe K, Mishima K, Tak aesu Y.	A Comparison between Perceptions of Psych iatric Outpatients and Psychiatrists Re garding Benzodiazepi ne Use and Decision Making for Its Discon tinuation: A Cross- Sectional Survey in Japan.	Int J Environ Res Public Health.	20(7)	5373	2023

<p>Sakurai Hitoshi, <u>Inada Ken</u>, <u>Aoki Yumi</u>, <u>Takeshima Masahiro</u>, <u>Ie Kenya</u>, <u>Kise Morito</u>, <u>Yoshida Eriko</u>, <u>Tsuboi Takashi</u>, <u>Yamada Hisashi</u>, <u>Hori Hikaru</u>, <u>Inada Yasushi</u>, <u>Shimizu Eiji</u>, <u>Mishima Kazuo</u>, <u>Watanabe Koichiro</u>, <u>Takeshi Yohsuke</u>, <u>Yoshikazu</u>.</p>	<p>Management of unspecified anxiety disorder; Expert consensus.</p>	<p>Neuropsychopharmacol Rev.</p>	<p>Feb 21.</p>		<p>2023</p>
<p><u>Aoki Y</u>, <u>Takeshi Y</u>, <u>Inada K</u>, <u>Yamada H</u>, <u>Muraoka T</u>, <u>Kikuchi T</u>, <u>Takeshima M</u>, <u>Tanaka M</u>, <u>Mishima K</u>, <u>Otsubo T</u>.</p>	<p>Development and acceptability of a decision aid for anxiety disorder considering discontinuation of benzodiazepine anxiolytic.</p>	<p>Frontiers in Psychiatry, in press.</p>			

<p><u>Tsuboi Takeshi</u>, <u>Takaesu Yoshikazu</u>, <u>Hasegawa Naomichi</u>, <u>Ochi Sinihiro</u>, <u>Fukumoto Kentaro</u>, <u>Ohi Kazutaka</u>, <u>Muraoka Hiroyuki</u>, <u>Okada Tsuyoshi</u>, <u>Kodaka Fumitoshi</u>, <u>Igarashi Shun</u>, <u>Iida Hitoshi</u>, <u>Kashiwagi Hiroko</u>, <u>Hori Hikaru</u>, <u>Ichihashi Kayo</u>, <u>Ogasawara Kazuyoshi</u>, <u>Hashimoto Naoki</u>, <u>Iga Jun-Ichi</u>, <u>Nakamura Toshinori</u>, <u>Usami Masahide</u>, <u>Nagasawa Tatsuya</u>, <u>Kido Mikiko</u>, <u>Komatsu Hiroshi</u>, <u>Yamagata Hiroto</u>, <u>Atake Kiyokazu</u>, <u>Furihata Ryuji</u>, <u>Kikuchi Saya</u>, <u>Horai Tadasu</u>, <u>Takeshima Masahiro</u>, <u>Hirano Yoji</u>, <u>Makinodan Manabu</u>, <u>Matsumoto Junya</u>, <u>Miura Kenichiro</u>, <u>Hishimoto Akitoyo</u>, <u>Numata Shusuke</u>, <u>Yamada Hisashi</u>, <u>Yasui-Furukori Norio</u>, <u>Inada Ken</u>, <u>Watanabe Koichiro</u>, <u>Hashimoto Ryota</u>.</p>	<p>Effects of electroconvulsive therapy on the use of anxiolytics and sleep medications: a propensity score-matched analysis.</p>	<p>Psychiatry Clin Neurosci.</p>	<p>Jan;77(1)</p>	<p>30-37</p>	<p>2023</p>
<p><u>Takeshima M</u>, <u>Yoshizawa K</u>, <u>Enomoto M</u>, <u>Ogasawara M</u>, <u>Kudo M</u>, <u>Itahoh Y</u>, <u>Ayabe N</u>, <u>Takaesu Y</u>, <u>Mishima K</u>.</p>	<p>Effects of Japanese policies and novel hypnotics on long-term prescriptions of hypnotics.</p>	<p>Psychiatry Clin Neurosci.</p>	<p>77(5)</p>	<p>264-272</p>	<p>2023</p>
<p><u>三島和夫</u></p>	<p>精神科薬物療法の出口戦略ガイドラインおよびその患者用資材作成経緯と臨床的背景</p>	<p>臨床精神薬理 (1343-3474)</p>	<p>24(9)</p>	<p>879-889</p>	<p>2021</p>

竹島正浩, 三島和夫	【向精神薬の保険適用と規制】向精神薬処方 の適正化と診療報酬	臨床精神薬理	24 (5)	499-504	2021
青木裕見	不眠症に対する認知行動療法 (CBT-I) 不眠症の 治療における shared decision making.	睡眠医療	15 (4)	463-469	2021
清水栄司, 井上猛	新しいエビデンスに基づいた不安症・強迫症の 診療ガイドライン (総論) (特集 不安症 治療の最新ガイドライン)	精神科 (科学評論社)	39 (2)	222-227	2021
関陽一, 清水栄司	パニック症の長期的展望 (特集 精神疾患患者の 人生全体を視野に入れた治療と支援)	臨床精神医学 (アークメディア)	50 (11)	1207-1212	2021
青木裕見	当事者中心の意思決定支援: デンジョン・エイド を活用したデンジョン・コーチング	精神科	41 (4)	533-542	2022
渡邊衡一郎, 青木裕見	共同意思決定 (Shared Decision Making : SDM) における対話	臨床精神薬理, 37(10), 1095-8, 2022.	37 (10)	1095-1098	2022
清水栄司	社交不安症 (さまざまな 場面で遭遇する精神疾患)	日本医師会雑誌	151・特別号 (2)	211-213	2022
清水栄司	認知行動療法の最新の 動向: 薬物療法を超える「会話療法」とデジタル・セラピューティックス の話題	日本内科学会雑誌	111 (11)	2311-2316	2022
高江洲義和	薬物療法についてどのように 当事者に説明すればよいのだろうか 不眠症における睡眠薬治療	臨床精神薬理	25(11)	1205-1212	2022
普天間国博, 高江洲義和	睡眠-覚醒障害 治療の基本 不眠症の薬物療法	精神科 Resident	3(3)	179-181	2022
竹島正浩, 高江洲義和	精神医学のフロンティア 認知行動療法は不安症患者のベンゾジアゼピン系薬剤 の中止を補助するか? システマティックレビューとメタ解析	精神神経学雑誌	124(5)	285-292	2022